CN116056694A - 消化脂肪酶活性阻遏剂、血中甘油三酯浓度升高抑制剂、及脂肪吸收抑制剂 - Google Patents
消化脂肪酶活性阻遏剂、血中甘油三酯浓度升高抑制剂、及脂肪吸收抑制剂 Download PDFInfo
- Publication number
- CN116056694A CN116056694A CN202180057519.1A CN202180057519A CN116056694A CN 116056694 A CN116056694 A CN 116056694A CN 202180057519 A CN202180057519 A CN 202180057519A CN 116056694 A CN116056694 A CN 116056694A
- Authority
- CN
- China
- Prior art keywords
- inhibitor
- linoleic acid
- oleic acid
- digestive
- lipase activity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000001079 digestive effect Effects 0.000 title claims abstract description 74
- 239000003112 inhibitor Substances 0.000 title claims abstract description 64
- 235000019626 lipase activity Nutrition 0.000 title claims abstract description 63
- 239000008280 blood Substances 0.000 title claims description 39
- 210000004369 blood Anatomy 0.000 title claims description 39
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 title claims description 36
- 238000010521 absorption reaction Methods 0.000 title claims description 35
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 claims abstract description 64
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 claims abstract description 64
- 239000005642 Oleic acid Substances 0.000 claims abstract description 63
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims abstract description 63
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims abstract description 62
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims abstract description 62
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims abstract description 62
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims abstract description 62
- 235000020778 linoleic acid Nutrition 0.000 claims abstract description 62
- 239000004480 active ingredient Substances 0.000 claims abstract description 40
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims abstract 9
- 239000000203 mixture Substances 0.000 claims description 41
- 235000019197 fats Nutrition 0.000 claims description 36
- 235000013305 food Nutrition 0.000 claims description 34
- 108090001060 Lipase Proteins 0.000 claims description 30
- 102000004882 Lipase Human genes 0.000 claims description 30
- 239000004367 Lipase Substances 0.000 claims description 30
- 235000019421 lipase Nutrition 0.000 claims description 30
- 230000000694 effects Effects 0.000 claims description 28
- 230000002401 inhibitory effect Effects 0.000 claims description 17
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 9
- 229940127557 pharmaceutical product Drugs 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 7
- 150000003626 triacylglycerols Chemical class 0.000 claims description 5
- ZQPPMHVWECSIRJ-MDZDMXLPSA-N elaidic acid Chemical compound CCCCCCCC\C=C\CCCCCCCC(O)=O ZQPPMHVWECSIRJ-MDZDMXLPSA-N 0.000 description 54
- 229940040461 lipase Drugs 0.000 description 22
- 239000000243 solution Substances 0.000 description 20
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 16
- 238000002835 absorbance Methods 0.000 description 13
- 241000700159 Rattus Species 0.000 description 12
- 239000003814 drug Substances 0.000 description 10
- 150000001875 compounds Chemical class 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 230000005764 inhibitory process Effects 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 230000029087 digestion Effects 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- -1 alpha-starch Polymers 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 230000000968 intestinal effect Effects 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- PEYUIKBAABKQKQ-AFHBHXEDSA-N (+)-sesamin Chemical compound C1=C2OCOC2=CC([C@H]2OC[C@H]3[C@@H]2CO[C@@H]3C2=CC=C3OCOC3=C2)=C1 PEYUIKBAABKQKQ-AFHBHXEDSA-N 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- PEYUIKBAABKQKQ-UHFFFAOYSA-N epiasarinin Natural products C1=C2OCOC2=CC(C2OCC3C2COC3C2=CC=C3OCOC3=C2)=C1 PEYUIKBAABKQKQ-UHFFFAOYSA-N 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 235000012054 meals Nutrition 0.000 description 5
- DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 5
- VRMHCMWQHAXTOR-CMOCDZPBSA-N sesamin Natural products C1=C2OCOC2=CC([C@@H]2OC[C@@]3(C)[C@H](C=4C=C5OCOC5=CC=4)OC[C@]32C)=C1 VRMHCMWQHAXTOR-CMOCDZPBSA-N 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 4
- 108050006759 Pancreatic lipases Proteins 0.000 description 4
- 102000019280 Pancreatic lipases Human genes 0.000 description 4
- 239000003674 animal food additive Substances 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 235000005687 corn oil Nutrition 0.000 description 4
- 239000002285 corn oil Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 108090000371 Esterases Proteins 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 208000008589 Obesity Diseases 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 235000003599 food sweetener Nutrition 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 235000010755 mineral Nutrition 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 235000020824 obesity Nutrition 0.000 description 3
- 229940116369 pancreatic lipase Drugs 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 239000013589 supplement Substances 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- JBYXPOFIGCOSSB-GOJKSUSPSA-N 9-cis,11-trans-octadecadienoic acid Chemical compound CCCCCC\C=C\C=C/CCCCCCCC(O)=O JBYXPOFIGCOSSB-GOJKSUSPSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 102100031416 Gastric triacylglycerol lipase Human genes 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- 240000004274 Sarcandra glabra Species 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 229940108924 conjugated linoleic acid Drugs 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 210000001198 duodenum Anatomy 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 235000021433 fructose syrup Nutrition 0.000 description 2
- 108010091264 gastric triacylglycerol lipase Proteins 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 210000002429 large intestine Anatomy 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000012085 test solution Substances 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241000383638 Allium nigrum Species 0.000 description 1
- 241000583531 Alpinia purpurata Species 0.000 description 1
- 244000080767 Areca catechu Species 0.000 description 1
- 235000006226 Areca catechu Nutrition 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 235000011274 Benincasa cerifera Nutrition 0.000 description 1
- 244000036905 Benincasa cerifera Species 0.000 description 1
- 244000089719 Bergera koenigii Species 0.000 description 1
- 235000008734 Bergera koenigii Nutrition 0.000 description 1
- 208000035985 Body Odor Diseases 0.000 description 1
- 241001113925 Buddleja Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 108010076119 Caseins Proteins 0.000 description 1
- 239000004380 Cholic acid Substances 0.000 description 1
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 235000015489 Emblica officinalis Nutrition 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 244000020551 Helianthus annuus Species 0.000 description 1
- 235000003222 Helianthus annuus Nutrition 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 240000000950 Hippophae rhamnoides Species 0.000 description 1
- 235000003145 Hippophae rhamnoides Nutrition 0.000 description 1
- 240000005979 Hordeum vulgare Species 0.000 description 1
- 235000007340 Hordeum vulgare Nutrition 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 235000010254 Jasminum officinale Nutrition 0.000 description 1
- 240000005385 Jasminum sambac Species 0.000 description 1
- 241000395050 Kaempferia parviflora Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 240000008415 Lactuca sativa Species 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 235000013628 Lantana involucrata Nutrition 0.000 description 1
- 240000005183 Lantana involucrata Species 0.000 description 1
- 235000004431 Linum usitatissimum Nutrition 0.000 description 1
- 240000006240 Linum usitatissimum Species 0.000 description 1
- 108010013563 Lipoprotein Lipase Proteins 0.000 description 1
- 102000043296 Lipoprotein lipases Human genes 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 235000006677 Monarda citriodora ssp. austromontana Nutrition 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- RJECHNNFRHZQKU-UHFFFAOYSA-N Oelsaeurecholesterylester Natural products C12CCC3(C)C(C(C)CCCC(C)C)CCC3C2CC=C2C1(C)CCC(OC(=O)CCCCCCCC=CCCCCCCCC)C2 RJECHNNFRHZQKU-UHFFFAOYSA-N 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 235000002725 Olea europaea Nutrition 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 235000019083 Osmanthus fragrans Nutrition 0.000 description 1
- 244000242564 Osmanthus fragrans Species 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 101710089165 Protein white Proteins 0.000 description 1
- 241000123887 Pulsatilla chinensis Species 0.000 description 1
- 244000294611 Punica granatum Species 0.000 description 1
- 235000014360 Punica granatum Nutrition 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 235000010842 Sarcandra glabra Nutrition 0.000 description 1
- 241001647091 Saxifraga granulata Species 0.000 description 1
- 235000003434 Sesamum indicum Nutrition 0.000 description 1
- 244000040738 Sesamum orientale Species 0.000 description 1
- 206010040904 Skin odour abnormal Diseases 0.000 description 1
- 108010073771 Soybean Proteins Proteins 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 239000004376 Sucralose Substances 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 244000191422 Terminalia bellirica Species 0.000 description 1
- 235000011517 Terminalia chebula Nutrition 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 241000157352 Uncaria Species 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 239000005862 Whey Substances 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 235000006886 Zingiber officinale Nutrition 0.000 description 1
- 244000273928 Zingiber officinale Species 0.000 description 1
- 235000010358 acesulfame potassium Nutrition 0.000 description 1
- 229960004998 acesulfame potassium Drugs 0.000 description 1
- 239000000619 acesulfame-K Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000000883 anti-obesity agent Substances 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 239000008122 artificial sweetener Substances 0.000 description 1
- 235000021311 artificial sweeteners Nutrition 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 229940082500 cetostearyl alcohol Drugs 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- RJECHNNFRHZQKU-RMUVNZEASA-N cholesteryl oleate Chemical compound C([C@@H]12)C[C@]3(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@H]3[C@@H]1CC=C1[C@]2(C)CC[C@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)C1 RJECHNNFRHZQKU-RMUVNZEASA-N 0.000 description 1
- 235000019416 cholic acid Nutrition 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 229960002471 cholic acid Drugs 0.000 description 1
- 235000017803 cinnamon Nutrition 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 244000195896 dadap Species 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000002781 deodorant agent Substances 0.000 description 1
- 230000001877 deodorizing effect Effects 0.000 description 1
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- QYDYPVFESGNLHU-UHFFFAOYSA-N elaidic acid methyl ester Natural products CCCCCCCCC=CCCCCCCCC(=O)OC QYDYPVFESGNLHU-UHFFFAOYSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000004426 flaxseed Nutrition 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 235000008397 ginger Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 244000237330 gutta percha tree Species 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- QYDYPVFESGNLHU-KHPPLWFESA-N methyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC QYDYPVFESGNLHU-KHPPLWFESA-N 0.000 description 1
- 229940073769 methyl oleate Drugs 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 229960002900 methylcellulose Drugs 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 1
- 150000002888 oleic acid derivatives Chemical class 0.000 description 1
- 150000002889 oleic acids Chemical class 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 1
- 229960001243 orlistat Drugs 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000000754 repressing effect Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 229940100486 rice starch Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 235000012045 salad Nutrition 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229940001941 soy protein Drugs 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 235000019408 sucralose Nutrition 0.000 description 1
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 229940100445 wheat starch Drugs 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A61K31/231—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having one or two double bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
本发明涉及含有选自由亚油酸及油酸组成的组中的至少一种作为有效成分的消化脂肪酶活性阻遏剂。
Description
技术领域
本发明涉及消化脂肪酶活性阻遏剂、血中甘油三酯浓度升高抑制剂、及脂肪吸收抑制剂。另外,本发明还涉及用于阻遏消化脂肪酶活性的食品组合物或医药品、用于抑制血中甘油三酯浓度升高的食品组合物或医药品、以及用于抑制脂肪吸收的食品组合物或医药品。
背景技术
伴随着饮食生活、生活习惯的变化等,全世界肥胖人口不断增加。肥胖是增加糖尿病、高血压、癌等各种各样的健康风险的风险因素,据称世界范围内每年400万人死于因肥胖引起的疾病。
作为现在使用的减肥药,已知:(1)作用于食欲中枢而抑制食欲的药物(马吲哚(Mazindol)等)、(2)通过阻遏肠内的脂肪酶从而抑制脂肪的吸收的药物(奥利司他(Orlistat)等);等等。这些减肥药中大多具有某些副作用,安全性尚未确定,因此能够长期使用的药物少。
上述之中,关于上述(2)的基于脂肪酶阻遏的脂肪吸收抑制剂,正在研究通过使用食品原材料来获得安全性更高的脂肪吸收抑制剂。作为具有脂肪酶阻遏能力的食品原材料,已知有杜仲叶(专利文献1)、白头翁、密蒙花、海桐皮、柏子仁、冬瓜子(专利文献2)、黑姜(kaempferia parviflora)、红姜、肉桂、大麦若叶、黑蒜、儿茶钩藤、紫阳花、诃子、石榴、亚麻仁、桂花、九节茶、虎耳草、茉莉花茶、牛至、橄榄叶、沙棘、咖哩叶(专利文献3)、及蔓九节(专利文献4)。
现有技术文献
专利文献
专利文献1:日本特开2005-289951号公报
专利文献2:日本特开2006-169181号公报
专利文献3:日本特开2010-209051号公报
专利文献4:日本特开2014-172901号公报
发明内容
发明所要解决的课题
然而,上述的食品原材料大多在市场中少有流通,可能会导致成本高及供给量的降低。此外,由于摄取充分量的食品原材料中所含的有效成分时,食品原材料本身的摄取量会成比例地增加,因此需要阐明并利用容易更有效地摄取的有效成分。因此,从获得容易性、成本降低、摄取效率等观点考虑,需要使用了来自更熟悉的食品的有效成分的、对脂肪吸收抑制等有用的制剂。
本发明的一方面是基于如上所述的情况而完成的,其目的在于提供新型消化脂肪酶活性阻遏剂、血中甘油三酯浓度升高抑制剂、及脂肪吸收抑制剂。
用于解决课题的手段
本申请的发明人发现,亚油酸或油酸、及它们的混合物具有阻遏消化脂肪酶活性的作用、及抑制血中甘油三酯浓度的升高的作用,并且,这些效果在同时使用亚油酸及油酸的情况下可更显著地发挥。另外,本申请的发明人由此发现这些成分具有作为脂肪吸收抑制剂的效果,从而完成了本发明。
即,本发明的一方面提供将选自由亚油酸及油酸组成的组中的至少一种作为有效成分的、消化脂肪酶活性阻遏剂。
本发明的另一方面提供将选自由亚油酸及油酸组成的组中的至少一种作为有效成分的、血中甘油三酯浓度升高抑制剂。
本发明的另一方面提供将选自由亚油酸及油酸组成的组中的至少一种作为有效成分的、脂肪吸收抑制剂。
本发明的另一方面提供含有选自由亚油酸及油酸组成的组中的至少一种作为有效成分的、用于阻遏消化脂肪酶活性的食品组合物或用于阻遏消化脂肪酶活性的医药品。
本发明的另一方面提供含有选自由亚油酸及油酸组成的组中的至少一种作为有效成分的、用于抑制血中甘油三酯浓度升高的食品组合物或用于抑制血中甘油三酯浓度升高的医药品。
本发明的另一方面为含有选自由亚油酸及油酸组成的组中的至少一种作为有效成分的、用于抑制脂肪吸收的食品组合物或用于抑制脂肪吸收的医药品。
上述的制剂、食品组合物或医药品可以含有亚油酸及油酸这两者作为有效成分。
发明效果
根据本发明,可以提供新型消化脂肪酶活性阻遏剂、血中甘油三酯浓度升高抑制剂、及脂肪吸收抑制剂。另外,根据本发明,还可以提供新型的用于阻遏消化脂肪酶活性的食品组合物或医药品、新型的用于抑制血中甘油三酯浓度升高的食品组合物或医药品、以及新型的用于抑制脂肪吸收的食品组合物或医药品。
附图说明
[图1]为示出亚油酸、油酸带来的消化脂肪酶活性的阻遏效果的图表。
[图2]为示出亚油酸、油酸及其混合物带来的消化脂肪酶活性阻遏率的图表。
[图3]为示出亚油酸及油酸的混合物带来的血中甘油三酯浓度升高抑制效果的图表。
具体实施方式
以下,对本发明的实施方式进行了说明,但本发明并不限于以下的实施方式。
本发明的一个实施方式提供将选自由亚油酸及油酸组成的组中的至少一种作为有效成分的、消化脂肪酶活性阻遏剂。为了更有效地获得消化脂肪酶活性阻遏效果,消化脂肪酶活性阻遏剂也可以含有亚油酸及油酸这两者作为有效成分。
本说明书中的所谓消化脂肪酶,是指由胃、肠(包括十二指肠、小肠、大肠)、胰腺等参与消化的器官分泌、在消化道内发挥作用的脂肪酶,更具体而言,可举出由胃分泌的胃脂肪酶、由十二指肠、小肠或大肠分泌的肠脂肪酶、由胰腺分泌的胰脂肪酶等。也将主要在肠内发挥作用的肠脂肪酶及胰脂肪酶统称为“肠内脂肪酶”。消化脂肪酶不包括在消化道以外的脏器中发挥作用的脂肪酶、例如心肌细胞的脂蛋白脂肪酶、脂肪细胞脂肪酶等。消化脂肪酶活性阻遏剂是阻遏这些消化脂肪酶的活性的制剂。
本说明书中的亚油酸包括下式(1)所表示的化合物、该化合物的异构体、及下式(1)所表示的化合物的衍生物(亚油酸衍生物)。作为亚油酸,从更容易获得消化脂肪酶活性的阻遏作用的观点考虑,优选为下式(1)所表示的化合物。作为亚油酸的异构体,有共轭亚油酸和非共轭亚油酸。从更容易获得消化脂肪酶活性的阻遏作用的观点考虑,优选为非共轭亚油酸。作为亚油酸衍生物,有亚油酸的氧化物等。从更容易获得消化脂肪酶活性的阻遏作用的观点考虑,作为亚油酸衍生物,优选亚油酸的氧化物以外的衍生物。
[化学式1]
本说明书中的油酸包括下式(2)所表示的化合物、该化合物的异构体、及下述(2)所表示的化合物的衍生物(油酸衍生物)。作为油酸,从更容易获得消化脂肪酶活性的阻遏作用的观点考虑,优选为下式(2)所表示的化合物。作为油酸的异构体,可举出反式油酸等。作为油酸的衍生物,可举出油酸甲酯等。
[化学式2]
亚油酸及油酸可以是化学合成的,也可以是从芝麻、大豆等食品等中获得的。本说明书中的亚油酸及油酸意指游离亚油酸及游离油酸,不包括作为甘油三酯的构成部分的亚油酸及油酸。
消化脂肪酶活性阻遏剂中的有效成分的含量可根据消化脂肪酶活性阻遏剂的形态、使用目的等而适当设定,例如以消化脂肪酶活性阻遏剂总量为基准,可以为0.0001质量%以上、0.001质量%以上、0.01质量%以上、0.1质量%以上、或1质量%以上,也可以为100质量%以下、50质量%以下、或5质量%以下。
本实施方式涉及的消化脂肪酶活性阻遏剂可以仅含有上述的有效成分,只要不妨碍本发明的效果,也可以还含有其他成分。作为其他成分,也可以为能在食品组合物、准医药品或医药品中使用的原材料。作为能在食品组合物、准医药品或医药品中使用的原材料,没有特别限制,可举出例如氨基酸、蛋白质、碳水化合物、油脂、甜味剂、矿物质、维生素、香料、赋形剂、粘结剂、润滑剂、崩解剂、乳化剂、表面活性剂、基剂、助溶剂、混悬剂等。
作为蛋白质,可举出例如乳酪蛋白、乳清、大豆蛋白、小麦蛋白、蛋清等。作为碳水化合物,可举出例如玉米淀粉、纤维素、α化淀粉、小麦淀粉、米淀粉、马铃薯淀粉等。作为油脂,可举出例如色拉油、玉米油、大豆油、红花油、橄榄油、棕榈油等。作为甜味剂,可举出例如葡萄糖、蔗糖、果糖、高果糖浆、果葡糖浆等糖类、木糖醇、赤藻糖醇、麦芽糖醇等糖醇、三氯蔗糖、阿斯巴甜、糖精、阿色磺胺钾等人造甜味剂、甜菊甜味剂等。作为矿物质,可举出例如钙、钾、磷、钠、锰、铁、锌、镁等、及它们的盐类等。作为维生素,可举出例如维生素E、维生素C、维生素A、维生素D、维生素B类、生物素、烟酸等。作为赋形剂,可举出例如糊精、淀粉、乳糖、结晶纤维素等。作为粘结剂,可举出例如聚乙烯醇、明胶、羟丙基甲基纤维素、羟丙基纤维素、羧甲基纤维素钠、聚乙烯吡咯烷酮等。作为润滑剂,可举出例如硬脂酸镁、硬脂酸钙、滑石等。作为崩解剂,可举出例如结晶纤维素、琼脂、明胶、碳酸钙、碳酸氢钠、糊精等。作为乳化剂或表面活性剂,可举出例如蔗糖脂肪酸酯、柠檬酸、乳酸、甘油脂肪酸酯、聚甘油脂肪酸酯、山梨糖醇酐脂肪酸酯、丙二醇脂肪酸酯、卵磷脂等。作为基剂,可举出例如鲸蜡硬脂醇、羊毛脂、聚乙二醇等。作为助溶剂,可举出例如聚乙二醇、丙二醇、碳酸钠、柠檬酸钠等。作为混悬剂,可举出例如单硬脂酸甘油脂、聚乙烯醇、聚乙烯吡咯烷酮、甲基纤维素、羟甲基纤维素、海藻酸钠等。它们可单独使用1种或组合使用2种以上。
本实施方式涉及的消化脂肪酶活性阻遏剂的形状没有限制,可以是固体(粉末、颗粒等)、液体(溶液、混悬液等)、糊状(paste)等任意的形状,也可以是散剂、丸剂、颗粒剂、片剂、胶囊剂、含片剂、液体制剂、混悬剂等任意的剂型。
消化脂肪酶活性阻遏剂的施予对象可以为人或动物,优选为人。消化脂肪酶活性阻遏剂可以以肥胖患者用、糖尿病患者用、高血压患者用等的形式而使用,也可以以没有肥胖等健康上的问题的健康人用的形式而使用。
消化脂肪酶活性阻遏剂可以进行经口施予,也可以进行静脉施予等非经口施予。消化脂肪酶活性阻遏剂优选进行经口施予。
经口施予消化脂肪酶活性阻遏剂的情况下,优选以每1次有效成分为50μg以上的方式进行施予,更优选以成为200μg以上的方式进行施予,进一步优选以成为1000μg以上的方式进行施予。另外,优选以每1日有效成分为150μg以上的方式进行施予,更优选以成为600μg以上的方式进行施予,进一步优选以成为3000μg以上的方式进行施予。另外,优选以每1次有效成分为300mg以下的方式进行施予,进一步优选以成为100mg以下的方式进行施予。另外,优选以每1日有效成分为900mg以下的方式进行施予,更优选以成为300mg以下以下的方式进行施予。只要在该范围内,就可以充分阻遏消化脂肪酶活性。
非经口施予消化脂肪酶活性阻遏剂的情况下,优选以每1次有效成分为50μg以上的方式进行施予,更优选以成为200μg以上的方式进行施予,进一步优选以成为1000μg以上的方式进行施予。另外,优选以每1日有效成分为150μg以上的方式进行施予,更优选以成为600μg以上的方式进行施予,进一步优选以成为3000μg以上的方式进行施予。另外,优选以每1次有效成分为300mg以下的方式进行施予,进一步优选以成为100mg以下的方式进行施予。另外,优选以每1日有效成分为900mg以下的方式进行施予,更优选以成为300mg以下的方式进行施予。只要在该范围内,就可以充分阻遏消化脂肪酶活性。
消化脂肪酶活性阻遏剂可以通过阻遏胃脂肪酶、肠脂肪酶、胰脂肪酶等消化脂肪酶的活性从而抑制血中的甘油三酯浓度的升高。即,本发明的一个实施方式可以提供将选自由亚油酸及油酸组成的组中的至少一种作为有效成分的、血中甘油三酯浓度升高抑制剂。
一个实施方式涉及的血中甘油三酯浓度升高抑制剂中,有效成分及其含量、施予对象、施予量等具体方式可以与上述的消化脂肪酶活性阻遏剂的方式相同。即,就一个实施方式涉及的血中甘油三酯浓度升高抑制剂而言,可以在上述的与消化脂肪酶活性阻遏剂有关的说明中将“消化脂肪酶活性阻遏剂”替换为“血中甘油三酯浓度升高抑制剂”。
此外,本实施方式涉及的消化脂肪酶活性阻遏剂、或血中甘油三酯浓度升高抑制剂可以通过阻遏消化脂肪酶活性、以及抑制血中甘油三酯浓度的升高从而抑制向体内的脂肪吸收。即,本发明的一个实施方式可以提供将选自由亚油酸及油酸组成的组中的至少一种作为有效成分的、脂肪吸收抑制剂。
一个实施方式涉及的脂肪吸收抑制剂中,有效成分及其含量、施予对象、施予量等具体方式可以与上述的消化脂肪酶活性阻遏剂的方式相同。即,就一个实施方式涉及的脂肪吸收抑制剂而言,可以在上述的与消化脂肪酶活性阻遏剂有关的说明中将“消化脂肪酶活性阻遏剂”替换为“脂肪吸收抑制剂”。
上述的消化脂肪酶活性阻遏剂、血中甘油三酯浓度升高抑制剂、及脂肪吸收抑制剂可以用于减肥、瘦身的用途。除此以外,也可以用于改善肤质、改善心血管疾病、改善胰岛素抵抗性、预防糖尿病、预防脑梗塞、预防脂肪肝、防止肝硬化、防止高血压、体臭用除臭剂的用途。
上述的消化脂肪酶活性阻遏剂、血中甘油三酯浓度升高抑制剂、及脂肪吸收抑制剂可以作为用于阻遏消化脂肪酶活性、用于抑制血中甘油三酯浓度升高、或用于抑制脂肪吸收的食品组合物、准医药品、或医药品而使用,用于动物的情况下,也可以作为饲料、饲料添加物而使用。上述的各制剂可以作为食品组合物、准医药品、医药品、饲料或饲料添加物等各制品的一个成分而使用。即,根据本发明的一个实施方式,可提供含有选自由亚油酸及油酸组成的组中的至少一种作为有效成分的、用于阻遏消化脂肪酶活性、用于抑制血中甘油三酯浓度升高、或用于抑制脂肪吸收的食品组合物、准医药品、医药品、饲料或饲料添加物。
用于阻遏消化脂肪酶活性、用于抑制血中甘油三酯浓度升高、或用于抑制脂肪吸收的食品组合物可以是健康食品、功能性标识食品、特殊用途食品、营养辅助食品、补充剂及特定保健用食品。作为食品组合物的具体例,可举出例如米类、面包类、面条类、乳制品、豆制品、点心类、饮料类、油脂食品、调味料、补充剂类等。
作为用于阻遏消化脂肪酶活性、用于抑制血中甘油三酯浓度升高、或用于抑制脂肪吸收的医药品或准医药品,可举出素片、糖衣片、颗粒、粉末、片剂(tablet)、胶囊(硬胶囊、软胶囊)等。
作为用于阻遏消化脂肪酶活性、用于抑制血中甘油三酯浓度升高、或用于抑制脂肪吸收的饲料或饲料添加物,可举出狗粮、猫粮等伴侣动物用饲料、家畜用饲料、家禽用饲料、养殖鱼类和贝类用饲料等。“饲料”包括动物出于营养目的而经口地摄取的所有物质。更具体而言,若根据营养成分的方面进行分类,则包括所有粗饲料、浓缩饲料、无机物饲料、特殊饲料,另外,若根据官方标准进行分类,则包括所有配合饲料、混合饲料、单一饲料。另外,若根据饲喂方法的方面进行分类,则包括所有的直接进行饲喂的饲料、与其他饲料混合而进行饲喂的饲料、或用于添加于饮料水中补充营养成分的饲料。
上述的各制品中的有效成分的含量可就上述的消化脂肪酶活性阻遏剂、血中甘油三酯浓度升高抑制剂、或脂肪吸收抑制剂中的有效成分的优选施予量在能摄取的范围内根据各制品而适当设定。
上述的各制品的制造方法没有特别限定,可以适当按照已知的方法。例如,可以通过在这些制造工序中以适宜的添加量添加选自亚油酸及油酸中的至少一种从而进行制造。
上述的本发明还涵盖包括将含有选自由亚油酸及油酸组成的组中的至少一种作为有效成分的组合物施予至需要其的对象的步骤的、消化脂肪酶活性的阻遏方法、抑制血中甘油三酯浓度的升高的方法、或抑制脂肪吸收的方法。
另外,上述的本发明还涵盖为了阻遏消化脂肪酶活性而使用的、为了抑制血中甘油三酯浓度的升高而使用的、或为了抑制脂肪吸收而使用的、含有选自由亚油酸及油酸组成的组中的至少一种作为有效成分的组合物。
进一步地,上述的本发明还涵盖选自由亚油酸及油酸组成的组中的至少一种在消化脂肪酶活性阻遏剂、血中甘油三酯浓度升高抑制剂、或脂肪吸收抑制剂的制造中的用途(应用)。
实施例
以下,利用实施例更具体地对本发明进行说明。然而,本发明并不受下述的实施例的限定。
<试验1:基于亚油酸、油酸的消化脂肪酶活性阻遏试验>
针对亚油酸及油酸,通过下述的方法评价消化脂肪酶阻遏活性。需要说明的是,作为亚油酸及油酸,使用了FUJIFILM Wako Pure Chemical Corporation制的亚油酸及油酸。
(消化脂肪酶液的制备)
向大鼠肠道丙酮粉(Sigma公司制)30mg中加入0.1M柠檬酸缓冲液(pH6.0)30mL,在冰中振荡1小时,然后以4℃、10000rpm离心分离45分钟,获得消化脂肪酶液。该消化脂肪酶液是胰脂肪酶、肠脂肪酶等的混合物。
(活性评价)
向1.5mL容量管(tube)中添加亚油酸0.19mg/mL或油酸0.16mg/mL的DMSO溶液(浓度为反应时的最终浓度)或者作为比较对象的芝麻素(sesamin)0.044mg/mL的二甲基亚砜(DMSO)溶液(浓度为反应时的最终浓度)10μL、显色液237μL、上述的消化脂肪酶液9μL、酯酶阻遏剂4μL和水90μL,于30℃孵育5分钟。然后,添加底物溶液25μL,遮光下于30℃进行30分钟反应。然后,加入反应终止液700μL,针对该液测定412nm的吸光度。作为显色液、底物溶液、酯酶阻遏剂、反应终止液,使用脂肪酶试剂盒S(SB Bioscience公司制)附带的物质。
(对照、空白评价)
出于测定上述的试样及试剂本身所具有的吸光度的目的,用新的1.5mL容量管制作对照。作为对照,添加亚油酸0.19mg/mL或油酸0.16mg/mL的DMSO溶液或者芝麻素0.044mg/mL的DMSO溶液10μL、显色液237μL、上述的消化脂肪酶液9μL、酯酶阻遏剂4μL、和水90μL,遮光下于30℃孵育35分钟。然后,加入反应终止液700μL、及底物溶液25μL,测定412nm的吸光度。另外,将除了代替各试样的DMSO溶液而仅添加DMSO以外与活性评价同样地进行调整而得的液体作为空白a,将仅添加DMSO与对照同样地进行制备而得的液体作为空白b(对照的空白)。针对空白a及空白b,也测定412nm的吸光度。
(计算)
利用以下的计算式算出添加有各试样时的消化脂肪酶活性。
消化脂肪酶活性(%)=100×(各试样的吸光度-对照的吸光度)/(空白a的吸光度-空白b的吸光度)
(结果)
将添加有各试样时的消化脂肪酶活性的计算结果示于图1中。添加有芝麻素(sesamin)时的消化脂肪酶活性为110.9%,与之相对,添加有亚油酸的情况下为8.9%,添加有油酸的情况下为7.1%,可知通过亚油酸或油酸的添加,消化脂肪酶活性降低。
<试验2:基于亚油酸及油酸的混合物的消化脂肪酶活性阻遏试验>
针对亚油酸及油酸的混合物,用与上述试验1同样的方法研究了消化脂肪酶活性阻遏效果。作为亚油酸及油酸,使用上述的物质。作为试样,分别使用0.009mg/mL的亚油酸水溶液、0.008mg/mL的油酸水溶液、及0.009mg/mL的亚油酸水溶液与0.008mg/mL的油酸水溶液的混合物(各试样中的浓度为反应测定时的最终浓度)。
(计算)
首先,利用下述所示的计算式算出各试样的消化脂肪酶活性阻遏率。
消化脂肪酶活性阻遏率(%)=100-{100×(各试样的吸光度-对照的吸光度)/(空白a的吸光度-空白b的吸光度)}
另外,为了评价是否可通过混合物而得到协同效果,使用Colby公式。实测值大于利用以下的Colby公式而算出的理论值的情况下,可以判断为有协同效果。
Colby公式:理论值E=A+B-(A×B)/100
A:亚油酸的消化脂肪酶活性阻遏率(%)
B:油酸的消化脂肪酶活性阻遏率(%)
(结果)
将结果示于图2。添加有亚油酸、油酸、及它们的混合物的情况下的消化脂肪酶活性阻遏率分别为9.6%、12.8%、30.6%。利用Colby公式而得到的、基于混合物的消化脂肪酶活性阻遏率的理论值为21.1%,因此可判断为亚油酸及油酸的混合物有消化脂肪酶活性阻遏作用的协同效果。
<试验3:基于亚油酸及油酸的混合物的大鼠的血中甘油三酯浓度升高抑制试验>
通过下述的试验评价亚油酸及油酸的混合物对大鼠是否具有血中甘油三酯浓度升高抑制效果。作为亚油酸及油酸,使用上述的物质。
(试验动物)
大鼠使用Wister Rat(雄性、6周龄)。在维持为环境温度:23℃、设定湿度:55%、明暗各12小时(照明:上午8点~下午8点)的饲养室中饲养大鼠。将自来水作为饮用水并使用自动给水装置而供其自由摄取。大鼠个别饲养,搬入后驯化5天以上。笼具及饲喂器的更换每周进行1次以上。
(脂质负荷餐的制作)
将玉米油30mL与胆酸400mg、胆固醇油酸酯10g及纯水30mL混合,对该混合物进行10分钟超声波处理,从而进行乳化,制成脂质负荷餐的乳化玉米油。
(试验方法)
测定大鼠的体重,以能施予亚油酸0.46mg/kg(大鼠体重)及油酸0.72mg/kg(大鼠体重)的方式计算施予用量。使亚油酸及油酸在20%(v/v)乙醇溶液中搅拌,制成试验液。将大鼠分为亚油酸·油酸施予组和对照组这两组(每组7只),向亚油酸·油酸施予组经口施予试验液400μL。向对照组经口施予20%(v/v)乙醇溶液400μL。对于所有组,在经口施予起10分钟后,经口施予作为脂质负荷餐的乳化玉米油1mL。自脂质负荷餐的施予起直至经过7.5小时后,每1.5小时进行大鼠的采血。将所采集的血液静置30分钟之后,进行离心分离(3000g×15分)。离心分离后取出血清,测定血中甘油三酯浓度(mg/dL)。血中甘油三酯浓度的测定按照LabAssayTMTriglyceride(FUJIFILM Wako Pure Chemical Corporation制)的测定方法而实施。
(结果)
将亚油酸·油酸施予组、及对照组中的血中甘油三酯浓度的变化示于图3。需要说明的是,由于对照组的受试体之中有1只为无法继续试验的状态,将其从对照组中排除。亚油酸·油酸施予组的血中甘油三酯浓度于脂质负荷餐施予后在6小时后较之对照组为显著低的值(P=0.04),在4.5小时后显示出抑制倾向(P=0.08)。由此可知,利用亚油酸及油酸的混合物抑制了血中甘油三酯浓度的升高。即,确认到可通过亚油酸及油酸抑制脂肪的吸收。
Claims (8)
1.消化脂肪酶活性阻遏剂,其含有选自由亚油酸及油酸组成的组中的至少一种作为有效成分。
2.血中甘油三酯浓度升高抑制剂,其含有选自由亚油酸及油酸组成的组中的至少一种作为有效成分。
3.脂肪吸收抑制剂,其含有选自由亚油酸及油酸组成的组中的至少一种作为有效成分。
4.如权利要求1~3中任一项所述的制剂,其含有亚油酸及油酸这两者作为有效成分。
5.用于阻遏消化脂肪酶活性的食品组合物或用于阻遏消化脂肪酶活性的医药品,其含有选自由亚油酸及油酸组成的组中的至少一种作为有效成分。
6.用于抑制血中甘油三酯浓度升高的食品组合物或用于抑制血中甘油三酯浓度升高的医药品,其含有选自由亚油酸及油酸组成的组中的至少一种作为有效成分。
7.用于抑制脂肪吸收的食品组合物或用于抑制脂肪吸收的医药品,其含有选自由亚油酸及油酸组成的组中的至少一种作为有效成分。
8.如权利要求5~7中任一项所述的食品组合物或医药品,其含有亚油酸及油酸这两者作为有效成分。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2020-131574 | 2020-08-03 | ||
JP2020131574A JP6928744B1 (ja) | 2020-08-03 | 2020-08-03 | 消化リパーゼ活性阻害剤、血中トリグリセリド濃度上昇抑制剤、及び脂肪吸収抑制剤 |
PCT/JP2021/028604 WO2022030442A1 (ja) | 2020-08-03 | 2021-08-02 | 消化リパーゼ活性阻害剤、血中トリグリセリド濃度上昇抑制剤、及び脂肪吸収抑制剤 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116056694A true CN116056694A (zh) | 2023-05-02 |
Family
ID=77456426
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202180057519.1A Pending CN116056694A (zh) | 2020-08-03 | 2021-08-02 | 消化脂肪酶活性阻遏剂、血中甘油三酯浓度升高抑制剂、及脂肪吸收抑制剂 |
Country Status (4)
Country | Link |
---|---|
US (1) | US20230277493A1 (zh) |
JP (1) | JP6928744B1 (zh) |
CN (1) | CN116056694A (zh) |
WO (1) | WO2022030442A1 (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPWO2023163055A1 (zh) | 2022-02-25 | 2023-08-31 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101579020A (zh) * | 2009-06-24 | 2009-11-18 | 金国祥 | 不含饱和脂肪酸的食用油 |
CN103284151A (zh) * | 2013-06-01 | 2013-09-11 | 赵全成 | 一种具有降血脂作用的ω-3不饱和植物组合油 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2014079207A (ja) * | 2012-10-17 | 2014-05-08 | Kayoko Nakamura | 凝固状加工食品 |
JP2019062741A (ja) * | 2016-02-17 | 2019-04-25 | 池田食研株式会社 | 膵リパーゼ阻害用組成物及び膵リパーゼ阻害用組成物の製造方法 |
-
2020
- 2020-08-03 JP JP2020131574A patent/JP6928744B1/ja active Active
-
2021
- 2021-08-02 WO PCT/JP2021/028604 patent/WO2022030442A1/ja active Application Filing
- 2021-08-02 US US18/018,951 patent/US20230277493A1/en active Pending
- 2021-08-02 CN CN202180057519.1A patent/CN116056694A/zh active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101579020A (zh) * | 2009-06-24 | 2009-11-18 | 金国祥 | 不含饱和脂肪酸的食用油 |
CN103284151A (zh) * | 2013-06-01 | 2013-09-11 | 赵全成 | 一种具有降血脂作用的ω-3不饱和植物组合油 |
Non-Patent Citations (1)
Title |
---|
XUAN LI等: "Free Linoleic Acid and Oleic Acid Reduce Fat Digestion and Absorption In Vivo as Potent Pancreatic Lipase Inhibitors Derived from Sesame Meal", MOLECULES, vol. 27, pages 4910 * |
Also Published As
Publication number | Publication date |
---|---|
JP2022028259A (ja) | 2022-02-16 |
WO2022030442A1 (ja) | 2022-02-10 |
US20230277493A1 (en) | 2023-09-07 |
JP6928744B1 (ja) | 2021-09-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR20080057232A (ko) | 체내 지질 개선 조성물 | |
WO2012097064A1 (en) | Nutritional compositions and methods for controlling blood glucose | |
US20080031860A1 (en) | Compositions Comprising Pantothenic Acid or Derivatives Thereof and Their Use for Stimulating Appetite | |
EP1677780A2 (en) | Dietary and other compositions, compounds, and methods for reducing body fat, controlling appetite, and modulating fatty acid metabolism | |
JPWO2005110400A1 (ja) | リパーゼ阻害剤、コレステロールエステラーゼ阻害剤、中性脂肪吸収抑制剤、コレステロール吸収抑制剤及びコレステロールエステル吸収抑制剤 | |
JP2006304792A (ja) | 内臓脂肪蓄積抑制食品 | |
US8722614B2 (en) | Adiponectin production enhancer | |
CN105935364B (zh) | 用于预防或治疗非酒精性肝病的包含人参皂苷f2的组合物 | |
JP2023157951A (ja) | 肝臓機能改善用組成物 | |
BR112020016923A2 (pt) | Método para reverter ou atenuar lesão, ou fraqueza ou perda óssea, ou para evitar fraturas em um indivíduo, e, composição | |
CA2302641C (en) | Liver fat accumulation inhibitory composition, food additive for liver fat accumulation inhibition, and method of inhibiting liver fat accumulation | |
CN1794926A (zh) | 提高饱腹感的食品 | |
JP2006182679A (ja) | ストレス性胃炎予防・治療剤 | |
CN116056694A (zh) | 消化脂肪酶活性阻遏剂、血中甘油三酯浓度升高抑制剂、及脂肪吸收抑制剂 | |
EP1378236A1 (en) | Agents against stress-induced diseases drugs | |
US20060189566A1 (en) | Muscle building agent and preventive or remedy for muscle weakening | |
JP2006273840A (ja) | 米タンパク質組成物およびその用途 | |
EP1090635B1 (en) | Use of ferulic acid for treating hypertension | |
KR20060119706A (ko) | 생활 습관병 예방ㆍ개선용의 유지 가공 조성물 | |
JP2002265985A (ja) | アポリポ蛋白質b分泌抑制性脂質組成物 | |
JP2010222284A (ja) | 血中gip上昇抑制剤 | |
WO2011122389A1 (ja) | 糖尿病の予防又は治療用油脂組成物 | |
JP2010163403A (ja) | イソプラスタン低下剤 | |
US20120122984A1 (en) | Methods of Treating Lipomas and Liposarcomas | |
JP5282202B2 (ja) | 抗ストレス剤または睡眠改善剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |